ONCR-177 + pembrolizumab

ONCR-177 + pembrolizumab is a **combination therapy** under investigation for the treatment of advanced and refractory solid tumors. **ONCR-177** is an intratumorally administered, genetically engineered oncolytic Herpes Simplex Virus (oHSV) immunotherapy that stimulates multiple arms of the immune system through local release of immune-activating transgenes and direct tumor lysis. **Pembrolizumab** is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor to restore anti-tumor immune responses. The combination is designed to enhance local and systemic anti-tumor immunity and possibly broaden responses to immunotherapy. The combination is being developed for patients with advanced cutaneous, subcutaneous, or metastatic nodal solid tumors who are refractory to, ineligible for, or relapsed from standard of care therapies[3].

Other names

ONCR-177 plus pembrolizumabONCR177 plus pembrolizumabONCR 177 plus pembrolizumabONCR-177 and pembrolizumabONCR177 and pembrolizumabONCR 177 and pembrolizumab